Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol agreed to pay $350m upfront for global rights to Five Prime’s CSF1R antibody program, including FPA008, in a deal that builds on the companies’ previous clinical collaboration agreement.